drugset
drugset / Trial / NCT05034484

A Study of ALPN-303 in Adult Healthy Volunteers

NCT05034484 ↗

Phase 1 Completed 72 enrolled Alpine Immune Sciences, Inc.
RandomizedParallel-groupQuadruple-blindOther

Summary

This study is to assess the safety, tolerability, pharmacokinetics (the amount of drug in the blood), pharmacodynamics (how the drug effects the body) and immunogenicity (how the drug effects the immune system) of a single dose of an investigational drug called ALPN-303. Multiple dose levels will be tested.

Timeline

Start
2021-11-15
Primary completion
2023-02-27
Completion
2023-02-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Povetacicept Protein / enzyme biologic — —

Indications

No indication recorded.